Fosun Pharma (02196.HK): The drug registration application for the injection of nitroglycerin was approved by the National Medical Products Administration.

The Smart Finance News app learned that Fosun Pharma (02196.HK) has recently announced that its subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd., a holding company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company"), has obtained approval from the National Medical Products Administration for the drug registration application of sodium nitroprusside injection (referred to as "the drug"). The approved indications include: (1) hypertensive crisis such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension before and after pheochromocytoma surgery, for emergency blood pressure reduction, and can also be used for controlled hypotension during surgical anesthesia; (2) acute heart failure, including acute pulmonary edema, also used for acute heart failure in acute myocardial infarction or valvular (mitral or aortic valve) insufficiency.